Abstract:Striking number of mutations found in the spike protein of recently emerged SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.3 and BA.4/5 has raised serious concerns regarding the escape from current antibody therapies and vaccine protection. Here, we conducted comprehensive analysis on the extent of two major Omicron lineages BA.1/BA.1.1 and BA.2 to escape neutralization from the therapeutic antibodies approved by the regulatory authorities and convalescent plasma from SARS-CoV-2 patients infected during initial wave of pandemic in early 2020. We showed that Omicron BA.1/BA.1.1 were the most resistant in both magnitude and breadth against antibodies and convalescent plasma, followed by Beta, BA.2, Gamma, Delta and Alpha. While the majority of therapeutic antibodies lost binding and neutralization to Omicron variants, BRII combo (BRII-196 + BRII-198), S309, and AZ combo (COV2-2196 + COV2-2130) maintained neutralization despite of reduction due to either conserved epitope or combinational effect between the two designated antibodies. A single intraperitoneal injection of BRII combo as a prophylactic treatment protected animals from Omicron infection. Treated animals manifested normal body weight, survived infection up to 14 days, undetectable levels of infectious viruses in the lungs, and reduced lung pathology compared to the controls. Analyzing ACE2 from diverse host species showed that Omicron variants acquired ability to use mouse ACE2 for entry. These results demonstrate major antigenic shifts and potentially broadening the host range of two major Omicron lineages BA.1/BA.1.1 and BA.2, posing serious challenges to current antibody therapies and vaccine protection as well as increasing danger of spillover into the wildlife.

Up or Down: Where Comes Omicron?

Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 Omicron variant: recent progress and future perspectives

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances to Counter the SARS-CoV-2 Omicron Variant

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants

SARS-CoV-2 Omicron and its current known unknowns: A narrative review

SARS-CoV-2 Omicron variant: Immune escape and vaccine development

Molecular basis of receptor binding and antibody neutralization of Omicron

Immune Evasion of Neutralizing Antibodies by SARS-CoV-2 Omicron.

Characterization of the Enhanced Infectivity and Antibody Evasion of Omicron BA.2.75

The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant

Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants

Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s

Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike

Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants